Veterinary Pharmaceuticals Market Report 2026

Veterinary Pharmaceuticals Market Overview

• Veterinary Pharmaceuticals market size has reached to $34.92 billion in 2025 • Expected to grow to $46.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Pet Ownership Fuels Demand For Veterinary Pharmaceuticals • Market Trend: Innovative Veterinary Pharmaceutical Products Meeting Unique Pet Health Needs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Veterinary Pharmaceuticals Market?

Veterinary pharmaceuticals are a class of drugs that are pharmacologically active and used to control, prevent, and treat diseases in animals. They have an effect when administered to animals and are rapidly broken down into active ingredients due to small intestine metabolism. The main types of veterinary pharmaceuticals include veterinary vaccines, veterinary antibiotics, veterinary parasiticides, and other types. Veterinary vaccines provide protection against one or more diseases, which can lower the severity or prevent certain diseases entirely. The routes of administration include oral and other routes of administration for animal types, including companion animals and livestock animals. The vaccines include inactivated vaccines, attenuated vaccines, recombinant vaccines, and others that are provided by various end-users such as veterinary hospitals, veterinary clinics, pharmacies and drug stores.

What Is The Veterinary Pharmaceuticals Market Growth Forecast?

The veterinary pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $46.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to emerging biopharmaceutical technologies, increasing r&d in veterinary drugs, adoption of precision medicine for animals, growth in preventive veterinary healthcare, rising investments in companion animal pharmaceuticals. Major trends in the forecast period include development of novel veterinary drugs, growth of companion animal healthcare, rising use of combination therapies, expansion of oral and topical formulations, emphasis on rapid metabolism and bioavailability.

Global Veterinary Pharmaceuticals Market Segmentation

1) By Type: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Types 2) By Type Of Animal: Livestock, Companion Animals 3) By Type Of Vaccine: Inactivated Vaccines, Attenuated Vaccines, Recombinant Vaccines, Other Type Of Vaccines 4) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administrations 5) By End User: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores Subsegments: 1) By Veterinary Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines 2) By Veterinary Antibiotics: Penicillins, Cephalosporins, Tetracyclines, Fluoroquinolones, Macrolides 3) By Veterinary Parasiticides: Endoparasiticides, Ectoparasiticides, Endectocides, Antiprotozoals 4) By Other Types: Anti-Inflammatory Drugs, Analgesics, Hormonal Medications, Antifungals

What Is The Driver Of The Veterinary Pharmaceuticals Market?

The increasing pet ownership is expected to boost the growth of the veterinary pharmaceuticals market going forward. Pet ownership refers to the legal and ethical responsibility of individuals or households for the care, maintenance, and well-being of domesticated animals, commonly known as pets. The increasing pet ownership is rising due to people seeking companionship and emotional support. Increasing pet ownership drives greater demand for veterinary care, which in turn stimulates the growth of veterinary pharmaceuticals by expanding the market for medications, vaccines, and preventive treatments necessary to maintain the health and well-being of a larger and more diverse population of companion animals. For instance, in April 2025, according to the Canadian Animal Health Institute, a Canada-based trade association, in 2024, Canada was home to an estimated 7.2 million dogs and 8.2 million cats, making pets an integral part of more than half of Canadian households. Therefore, the increasing pet ownership is driving the growth of the veterinary pharmaceuticals industry.

Key Players In The Global Veterinary Pharmaceuticals Market

Major companies operating in the veterinary pharmaceuticals market are Zoetis Inc, Merck & Co. Inc, Boehringer Ingelheim International Gmb, Elanco Animal Health Incorporated, Ceva Sante Animale, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol S.A., Phibro Animal Health Corporation, Kyoritsu Seiyaku Corporation, Hebei Chengshengtang Animal Pharmaceutical, Shijiazhuang Fengqiang Animal Pharmaceutical Co .Ltd, Vvaan Lifesciences Private Limited, Century Pharmaceuticals Limited, Cargill India Pvt. Ltd., Jurox Pty Ltd, Bayer, Veteq, Nimrod Veterinary Products Ltd., Bimeda, Orion Animal Health, Petmedix, Eco Animal Health, Teknofarma, Farmavet, Candioli Pharma, Suanfarma, Marino Ibericamed, MPA veterinary, Swetrade Pharmaceuticals AB, Animalcare, VET-AGRO Sp. z o. o, CANPOLAND SA, Cymedica, VIC Group, NITA-FARM, Apicenna LLC, Delos Medica, Provet Group, Bioveta AS, Veterinarski Zavod Subotica, PharmaGal s.r.o., Trifecta Pharmaceuticals USA LLC., Alberta Veterinary Laboratories Ltd., Veterinary Purchasing Co. Ltd, UCBVET, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, Lemavet, Primo Veterinary Medicines Trading LLC., AL Kubara Veterinary Medicines Trading LLC., Eurovets Veterinary Suppliers, Saudi Pharmaceutical Industries, DBK Pharma S.A.E., Dawa Limited, Neimeth International Pharmaceuticals, Osy-Adamu Pharmaceutical Co., Global Vet (U) Ltd.

Global Veterinary Pharmaceuticals Market Trends and Insights

Major companies operating in the veterinary pharmaceuticals market are developing new products such as molidustat oral suspensions to meet larger customer bases, more sales, and increase revenue. Molidustat oral suspension refers to a medication used for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. For instance, in September 2023, Elanco Animal Health Incorporated, a US-based pharmaceutical company, launched, Varenzin-CA1 (molidustat oral suspension), the first and only medication to manage non-regenerative anemia in cats with chronic kidney disease (CKD) and received provisional approval from the U.S. Food and Drug Administration (FDA). Varenzin-CA1 has the unique feature of being an innovative needle-free oral suspension solution for cats that can be administered at home without the requirement for in-clinic injections. This is also the first medication for cats to receive expanded conditional approval, a route to the market that promotes the creation of novel therapies and broadens the options for treating animals with unusual conditions, serious or life-threatening illnesses, or illnesses for which there are no effective or available treatments.

What Are Latest Mergers And Acquisitions In The Veterinary Pharmaceuticals Market?

In April 2025, Swedencare AB (publ), a Sweden based provider of animal health and wellness products including pharmaceuticals, supplements, and specialty veterinary formulations for companion animals, acquired Summit Veterinary Pharmaceuticals Limited for approximately $38 million (£30 million). With this acquisition, Swedencare sought to strengthen its veterinary pharmaceuticals portfolio and deepen its presence in the UK and Hong Kong markets by integrating Summit’s established specialty pharma business enhancing product offerings for veterinary professionals and expanding its geographic footprint in key growth regions. Summit Veterinary Pharmaceuticals Limited is a UK-based developer, manufacturer, and seller of customized specialty veterinary pharmaceutical products exclusively for veterinary professionals in the UK and Hong Kong.

Regional Outlook

North America was the largest region in the veterinary pharmaceuticals market in 2025. Asia-Pacific was the second-largest region in the global veterinary pharmaceuticals market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Veterinary Pharmaceuticals Market?

The veterinary pharmaceuticals market consists of sales of biological drugs, biosimilars, monoclonal antibodies, sedatives, and antihistaminic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.